MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by JEFFERY, E. H.
Right arrow Articles by MANNERING, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by JEFFERY, E. H.
Right arrow Articles by MANNERING, G. J.

Molecular Pharmacology, Vol 15, 396-409, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics

Mechanism of the Nucleotide Pyrophosphatase Induced Distortion of Stoichiometry of TPNH Utilization and Product Formation by Hepatic Cytochrome P-450 Linked N-Demethylase Systems

ELIZABETH H. JEFFERY 1 and GILBERT J. MANNERING 1

1 Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota 55455

By definition, an hepatic cytochrome P-450-and TPNH-linked monooxygenase reaction requires that a mole of TPNH be utilized for each mole of product formed. When rat hepatic microsomes have been used to study the stoichiometry of N-demethylase reactions, considerably more TPNH utilization has usually been observed than can be accounted for by product (HCHO) formation. The presence of nucleotide pyrophosphatase in microsomes has been shown to cause the apparent substrate-induced enhancement of endogenous TPNH oxidation. Demethylation of the substrate (aminopyrine, benzphetamine, codeine or ethylmorphine) increases the rate of TPNH oxidation and this enhances the rate limitation of TPNH for the pyrophosphatase reaction (a first order reaction) without inflicting a TPNH rate limitation on the endogenous oxidation of TPNH (a zero order reaction). As a consequence, tess 2'5' ADP—an inhibitor of TPNH oxidation—is formed from TPNH by the pyrophosphatase when the substrate is present than when it is absent. Because less 2'5' ADP is formed in the presence of substrate, less inhibition of endogenous TPNH oxidation occurs; substrate thus appears to stimulate endogenous TPNH oxidation when in fact it is only permitting the reaction to proceed at a less inhibited rate. When EDTA (0.2 mM) or 5' AMP (1 mM) is used to inhibit pyrophosphatase activity, a stoichiometry of TPNH oxidized:HCHO formed of unity was observed when microsomes from several mammalian species were used. Unity was also observed when the influence of pyrophosphatase was diminished by increasing the ratio of demethylase activity to pyrophosphatase activity in microsomes by administering phenobarbital to rats; by modulating the ratios of the two enzymes in this manner, it was shown that disparity in the 1:1 ratio of TPNH oxidation: HCHO formation is directly related to the nucleotide pyrophosphatase content of the microsomes. When EDTA or 5' AMP is added to the medium, the rate of monooxygenase activity of hepatic microsomes can be measured by monitoring the disappearance of the absorbance of TPNH at 340 nm.

Submitted on June 7, 1978
Accepted on October 2, 1978







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics